top of page

Mwandishi

Mhariri:

ULY CLINIC

Dkt. Benjamin L, MD

17 Machi 2021, 19:07:30

Metronidazole na ujauzito

Metronidazole na ujauzito

Ingawa hitimisho la baadhi ya ripoti zilizowasili zinachanganya kuhusu usalama wa metronidazole kwenye ujauzito, machapisho mbalimbali yanaonyesha dawa hii ina hatari kidogo ya kusababisha madhaifu ya maumbile kwa kijusi tumboni. Kwa sasa pia ni vigumu kuchunguza madai kuhusu hatari ya metronidazole kusababisha saratani kwa watoto, kwa sababu ya uchache wa watoto wanaozaliwa na saratani na uhaba wa taarifa hizo kutoka wamama waliotumia dawa hii, na kukosekana kwa tafiti zilizoangalia matumizi ya metronidazole na mchango wa sababu za kimazingira ambazo zinaweza changia kwa pamoja kusababisha saratani kwa watoto. Mzalishaji wa dawa anasema kwamba dawa hii haipaswi kutumika kwenye kipindi cha kwanza cha ujauzito kutibu ugonjwa wa trichomoniasis au vaginosis iliyosababishwa na bakteria, hata hivyo anashauri kutumika kwenye kipindi cha pili (2) na tatu(3) cha ujauzito kutibu magonjwa hayo. Endapo itahitajika kwa kazi nyingine, dawa hii itumike pale tu endapo hakuna dawa nyingine mbadala wake.


Ushauri dhidi ya matumizi kwa mama mjamzito


Taarifa za binadamu zinaonyesha hatari kidogo ya madhara kwa kijusi-kichanga


Taarifa za binadamu zinaonyesha hatari kidogo ya madhara kwa kijusi-kichanga ina maanisha nini?

Kuna taarifa chache za uzoefu wa matumizi kwa binadamu kutoka kwenye dawa hii au dawa zilizo kundi moja au zinazofanana ufanyaji kazi. Ikijumuisha ujauzito miezi mitatu ya kwanza, inaonyesha kuwa, dawa hii haiwakilishi kuwa na hatari yenye mashiko ya kuwa sumu kwa kichanga tumboni kuweza kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo endapo itatumika muda wowote ule kwenye ujauzito. Taarifa chache za uzoefu wa matumizi kwa binadamu zinafanya taarifa za uzazi wa wanyama kutokuwa na mashiko.


Ushauri wa matumizi kwa mama anayenyonyesha

Usinyonyeshe unapotumia dawa hii(Kwa matumizi ya dozi moja tu)

Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu(kwa wanaotumia dozi ya mgawanyo)

Usinyonyeshe unapotumia dawa hii(Kwa matumizi ya dozi moja tu) na

Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu(kwa wanaotumia dozi ya mgawanyo) ina maanisha nini?


Usinyonyeshe unapotumia dawa hii(Kwa matumizi ya dozi moja tu) ina maanisha nini?

Dawa hii inaweza kuwa haiingii kwenye maziwa au kuingia kwenye maziwa ya mama kwa kiasi kidogo sana, hata hivyo faida za matumizi ya dawa hii kwa mama zinazidi kwa kiasi kikubwa kunyonyesha mtoto. Unyonyeshaji unapaswa kusimamishwa mpaka mama atakapomaliza dozi ya dawa hii na kiwango katika damu kuwa chini ya kiwango cha kitiba.



Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu(kwa wanaotumia dozi ya mgawanyo) ina maanisha nini?

Hakuna taarifa za uzoefu kuhusu matumizi ya dawa hii kwa mama anayenyonyesha au kuna taarifa chache. Sifa za ufanyaji kazi wa dawa zinaonyesha kuwa dawa hii inaweza kuwa sumu kwa kichanga anayenyonya. Dawa hii isitumike kwa mama anayenyonyesha.

ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

4 Juni 2025, 19:17:27

​

  1. Amon K, et al. Maternal-fetal passage of metronidazole. In: Advances in Antimicrobial and Antineoplastic Chemotherapy. Proceedings of the VII International Congress of Chemotherapy, Prague; 1971. p. 113–5.

  2. Heisterberg L. Placental transfer of metronidazole in the first trimester of pregnancy. J Perinat Med. 1984;12:43–5.

  3. Karhunen M. Placental transfer of metronidazole and tinidazole in early human pregnancy after a single infusion. Br J Clin Pharmacol. 1984;18:254–7.

  4. Amon I, et al. Pharmacokinetics of metronidazole in pregnant women. Chemotherapy. 1981;27:73–9.

  5. Visser AA, Hundt HKL. The pharmacokinetics of a single intravenous dose of metronidazole in pregnant patients. J Antimicrob Chemother. 1984;13:279–83.

  6. Anonymous. Is Flagyl dangerous? Med Lett Drugs Ther. 1975;17:53–4.

  7. Finegold SM. Metronidazole. Ann Intern Med. 1980;93:585–7.

  8. Beard CM, et al. Lack of evidence for cancer due to use of metronidazole. N Engl J Med. 1979;301:519–22.

  9. Carvajal A, et al. Metronidazole during pregnancy. Int J Gynecol Obstet. 1995;48:323–4.

  10. Thapa PB, et al. Prenatal exposure to metronidazole and risk of childhood cancer. A retrospective cohort study of children younger than 5 years. Cancer. 1998;83:1461–8.

  11. Berbel-Tornero O, et al. Prenatal exposure to metronidazole and risk of childhood cancer. A retrospective cohort study of children younger than 5 years. Cancer. 1999;85:2494–5.

  12. Gray MS. Trichomonas vaginalis in pregnancy: the results of metronidazole therapy on the mother and child. J Obstet Gynaecol Br Commonw. 1961;68:723–9.

  13. Robinson SC, Johnston DW. Observations on vaginal trichomoniasis. II. Treatment with metronidazole. Can Med Assoc J. 1961;85:1094–6.

  14. Luthra R, Boyd JR. The treatment of trichomoniasis with metronidazole. Am J Obstet Gynecol. 1962;83:1288–93.

  15. Schram M, Kleinman H. Use of metronidazole in the treatment of trichomoniasis. Am J Obstet Gynecol. 1962;83:1284–7.

  16. Andrews MC, Andrews WC. Systemic treatment of trichomonas vaginitis. South Med J. 1963;56:1214–8.

  17. Zacharias LF, et al. Trichomoniasis and metronidazole. Am J Obstet Gynecol. 1963;86:748–52.

  18. Kotcher E, et al. The effect of metronidazole on vaginal microbiology and maternal and neonatal hematology. Am J Obstet Gynecol. 1964;88:184–9.

  19. Scott-Gray M. Metronidazole in obstetric practice. J Obstet Gynaecol Br Commonw. 1964;71:82–5.

  20. Perl G. Metronidazole treatment of trichomoniasis in pregnancy. Obstet Gynecol. 1965;25:273–6.

  21. Peterson WF, et al. Metronidazole in pregnancy. Am J Obstet Gynecol. 1966;94:343–9.

  22. Robinson SC, Mirchandani G. Trichomonas vaginalis. V. Further observations on metronidazole (Flagyl)(including infant follow-up). Am J Obstet Gynecol. 1965;93:502–5.

  23. Mitchell RW, Teare AJ. Amoebic liver abscess in pregnancy. Case reports. Br J Obstet Gynaecol. 1984;91:393–5.

  24. Morgan I. Metronidazole treatment in pregnancy. Int J Gynaecol Obstet. 1978;15:501–2.

  25. Sands RX. Pregnancy, trichomoniasis, and metronidazole. Am J Obstet Gynecol. 1966;94:350–3.

  26. Berget A, Weber T. Metronidazole and pregnancy. Ugeskr Laeger. 1972;134:2085–9. As cited in Shepard TH. Catalog of Teratogenic Agents. 6th ed. Baltimore, MD: Johns Hopkins University Press; 1989. p. 426.

  27. Heinonen OP, et al. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group; 1977. p. 298, 299, 302.

  28. Cantu JM, Garcia-Cruz D. Midline facial defect as a teratogenic effect of metronidazole. Birth Defects. 1982;18:85–8.

  29. Greenberg F. Possible metronidazole teratogenicity and clefting. Am J Med Genet. 1985;22:825.

  30. Rosa FW, et al. Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet Gynecol. 1987;69:751–5.

  31. Piper JM, et al. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol. 1993;82:348–52.

  32. Burtin P, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172:525–9.

  33. Caro-Paton T, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44:179–82.

  34. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol. 1998;105:322–7.

  35. Kazy Z, et al. The possible association between the combination of vaginal metronidazole and miconazole treatment and polysyndactyly: population-based case-control teratologic study. Reprod Toxicol. 2005;20:89–94.

  36. Sorensen HT, Thulstrup AM, Schonheyder HC, Nielsen GL, Czeizel A, and the EUROMAP Study Group. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother. 1999;44:854–5.

  37. Damjanov I. Metronidazole and alcohol in pregnancy. JAMA. 1986;256:472.

  38. Diav-Citrin O, et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology. 2001;63:186–92.

  39. McDonald HM, et al. Bacterial vaginosis in pregnancy and efficacy of short-course oral metronidazole treatment: a randomized controlled trial. Obstet Gynecol. 1994;84:343–8.

  40. Morales WJ, et al. Effect of metronidazole in patients with history of preterm birth and bacterial vaginosis: a placebo control double blind study (abstract). Am J Obstet Gynecol. 1993;168:377.

  41. Morales WJ, et al. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol. 1994;171:345–9.

  42. Hauth J, et al. Efficacy of metronidazole plus erythromycin to decrease bacterial vaginosis and other markers of altered vaginal flora (abstract). Am J Obstet Gynecol. 1993;168:421.

  43. Hauth JC, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732–6.

  44. McDonald HM, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomized, placebo controlled trial. Br J Obstet Gynaecol. 1997;104:1391–7.

  45. Svare J, et al. Ampicillin-metronidazole treatment in idiopathic preterm labour: a randomized controlled multicentre trial. Br J Obstet Gynaecol. 1997;104:892–7.

  46. Klebanoff M, et al. Metronidazole did not prevent preterm birth in asymptomatic women with bacterial vaginosis (abstract). Am J Obstet Gynecol. 1999;180:S2.

  47. Hauth JC, et al. Response of the three components of a vaginal gram stain score to metronidazole treatment and in relation to preterm birth (abstract). Am J Obstet Gynecol. 2000;182:S56.

  48. Carey J, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med. 2000;342:534–40.

  49. Carey JC, et al. Metronidazole treatment increased the risk of preterm birth in asymptomatic women with trichomonas (abstract). Am J Obstet Gynecol. 2000;182:S13.

  50. Klebanoff MA, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345:487–93.

  51. Erickson SH, et al. Metronidazole in breast milk. Obstet Gynecol. 1981;57:48–50.

  52. Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mothers and infants. J Perinat Med. 1983;11:114–20.

  53. Moore B, Collier J. Drugs and breast-feeding. Br Med J. 1979;2:211.

  54. Clements CJ. Metronidazole and breast feeding. NZ Med J. 1980;92:329.

  55. Passmore CM, et al. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol. 1988;26:45–51.

  56. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.

bottom of page